Cargando…

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells

Genetic rearrangements involving the anaplastic lymphoma kinase (ALK) gene create oncogenic drivers for several cancers, including malignant peritoneal mesothelioma (MPeM). Here, we report genomic and functional precision oncology profiling on a rare case of a 5-year old patient diagnosed with wide-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murumägi, Astrid, Ungureanu, Daniela, Arjama, Mariliina, Bützow, Ralf, Lohi, Jouko, Sariola, Hannu, Kanerva, Jukka, Koskenvuo, Minna, Kallioniemi, Olli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851186/ https://www.ncbi.nlm.nih.gov/pubmed/33530027 http://dx.doi.org/10.1016/j.tranon.2021.101027

Ejemplares similares

STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
por: Rüschoff, Jan H., et al.
Publicado: (2019)

Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness
por: Karvonen, Hanna, et al.
Publicado: (2020)

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma
por: Kohtamäki, Laura, et al.
Publicado: (2021)

Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors
por: Jacome Sanz, Dafne, et al.
Publicado: (2021)

Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma
por: Murumägi, Astrid, et al.
Publicado: (2022)

Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review
por: Wu, Xiao, et al.
Publicado: (2023)

Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention
por: Raivola, Juuli, et al.
Publicado: (2022)

Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas
por: Pérot, Gaëlle, et al.
Publicado: (2014)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy
por: Gerthofer, Valeria, et al.
Publicado: (2021)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion
por: Li, XiaoQing, et al.
Publicado: (2023)

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
por: Zhang, Linlin, et al.
Publicado: (2022)

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
por: Zhu, Lucheng, et al.
Publicado: (2022)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
por: Zeng, Hao, et al.
Publicado: (2021)

STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
por: Su, Cuiyun, et al.
Publicado: (2020)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
por: Sun, Kunyan, et al.
Publicado: (2021)

E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models
por: Bruun, Jarle, et al.
Publicado: (2021)

Sleep-related breathing disorder in non-infectious pulmonary complications after pediatric allogeneic stem cell transplantation
por: Ukonmaanaho, Elli-Maija, et al.
Publicado: (2022)

Don Giovanni KV 527
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1992)

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
por: Lin, Ruihe, et al.
Publicado: (2023)

Silencing of STRN4 suppresses the malignant characteristics of cancer cells
por: Wong, Meihong, et al.
Publicado: (2014)

Reanalysis of RNA-Sequencing Data Reveals Several Additional Fusion Genes with Multiple Isoforms
por: Kangaspeska, Sara, et al.
Publicado: (2012)

Membrane-Type-3 Matrix Metalloproteinase (MT3-MMP) Functions as a Matrix Composition-Dependent Effector of Melanoma Cell Invasion
por: Tatti, Olga, et al.
Publicado: (2011)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib
por: Yang, Yan, et al.
Publicado: (2017)

Chromosomal rearrangements and their neoantigenic potential in mesothelioma
por: Mansfield, Aaron Scott, et al.
Publicado: (2020)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib
por: Song, Guo-qiang, et al.
Publicado: (2023)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Pro-oncogene Pokemon Promotes Prostate Cancer Progression by Inducing STRN4 Expression
por: Jiang, Fuquan, et al.
Publicado: (2019)

circStrn3 is involved in bone cancer pain regulation in a rat model
por: Zhang, Yiwen, et al.
Publicado: (2020)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mbfln2gfqpad6u002q96782qer